Brief reports

Fluoxetine in panic disorder

Franklin R. Schneier, Michael R. Liebowitz, Sharon O. Davies, Janet Fairbanks, Eric Hollander, Raphael Campeas, Donald F. Klein

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.

Original languageEnglish (US)
Pages (from-to)119-121
Number of pages3
JournalJournal of Clinical Psychopharmacology
Volume10
Issue number2
StatePublished - 1990
Externally publishedYes

Fingerprint

Fluoxetine
Panic Disorder
Agoraphobia
Serotonin Uptake Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Schneier, F. R., Liebowitz, M. R., Davies, S. O., Fairbanks, J., Hollander, E., Campeas, R., & Klein, D. F. (1990). Brief reports: Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology, 10(2), 119-121.

Brief reports : Fluoxetine in panic disorder. / Schneier, Franklin R.; Liebowitz, Michael R.; Davies, Sharon O.; Fairbanks, Janet; Hollander, Eric; Campeas, Raphael; Klein, Donald F.

In: Journal of Clinical Psychopharmacology, Vol. 10, No. 2, 1990, p. 119-121.

Research output: Contribution to journalArticle

Schneier, FR, Liebowitz, MR, Davies, SO, Fairbanks, J, Hollander, E, Campeas, R & Klein, DF 1990, 'Brief reports: Fluoxetine in panic disorder', Journal of Clinical Psychopharmacology, vol. 10, no. 2, pp. 119-121.
Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R et al. Brief reports: Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology. 1990;10(2):119-121.
Schneier, Franklin R. ; Liebowitz, Michael R. ; Davies, Sharon O. ; Fairbanks, Janet ; Hollander, Eric ; Campeas, Raphael ; Klein, Donald F. / Brief reports : Fluoxetine in panic disorder. In: Journal of Clinical Psychopharmacology. 1990 ; Vol. 10, No. 2. pp. 119-121.
@article{83685a2de25249c1a391be2965791987,
title = "Brief reports: Fluoxetine in panic disorder",
abstract = "Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76{\%}) experienced moderate to marked improvement in panic attacks. Four (16{\%}) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.",
author = "Schneier, {Franklin R.} and Liebowitz, {Michael R.} and Davies, {Sharon O.} and Janet Fairbanks and Eric Hollander and Raphael Campeas and Klein, {Donald F.}",
year = "1990",
language = "English (US)",
volume = "10",
pages = "119--121",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Brief reports

T2 - Fluoxetine in panic disorder

AU - Schneier, Franklin R.

AU - Liebowitz, Michael R.

AU - Davies, Sharon O.

AU - Fairbanks, Janet

AU - Hollander, Eric

AU - Campeas, Raphael

AU - Klein, Donald F.

PY - 1990

Y1 - 1990

N2 - Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.

AB - Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.

UR - http://www.scopus.com/inward/record.url?scp=0025216663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025216663&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 119

EP - 121

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -